Key Takeaways
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported first-quarter adjusted earnings of $1.99 per share, significantly beating the Zacks Consensus Estimate of $1.43 per share.
The results beat Wall Street expectations, with the average estimate of six analysts surveyed by Zacks Investment Research calling for earnings of $1.43 per share.
The RNA interference drug developer posted revenue of $1.17 billion in the period, which also beat Street forecasts of $1.13 billion. This performance marks a sharp reversal from the same period a year ago, when the company reported a loss of $0.01 per share.
Despite the strong quarter, Alnylam shares have declined 24 percent since the beginning of the year, though they have risen 17 percent in the last 12 months. The company did not provide updated financial guidance for the upcoming quarter.
A recent analysis of undervalued stocks based on discounted cash flow models estimated Alnylam's fair value at $601.17, suggesting it trades at a 49.7 percent discount even at its current price of approximately $302.11. The Cambridge, Massachusetts-based company specializes in RNA interference (RNAi) therapeutics, a novel class of medicines. The swing to profitability could increase investor confidence in its underlying technology platform and commercial execution.
The significant earnings beat and turnaround from a loss to a profit signal a new phase of financial health for the company. Investors will be closely watching for continued profitability in the company's Q2 2026 earnings report to see if the trend can be sustained.
This article is for informational purposes only and does not constitute investment advice.
